Annapurna S Pendri from 54 Aspen Dr, South Glastonbury, CT 06073, Phone: (860)6595800

Us Patents

Terminally-Branched Polymeric Linkers And Polymeric Conjugates Containing The Same
view source
US Patent:

6395266, May 28, 2002
Filed:

Apr 16, 1999
Appl. No.:

09/293624
Inventors:

Anthony J. Martinez - Hamilton Square NJ
Annapurna Pendri - Middletown CT
Richard B. Greenwald - Somerset NJ
Yun H. Choe - Piscataway NJ
Assignee:

Enzon, Inc. - Piscataway NJ
International Classification:

A61K 31785
US Classification:

424 783, 5147723, 514283, 514506, 514513, 514515
Abstract:

The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: E are independently selected from the group consisting of hydrogen, C alkyls, C branched alkyls, C cycloalkyls, C substituted alkyls, C substituted cycloalkyls, aryls, substituted aryls, aralkyls, C heteroalkyls, substituted C heteroalkyls, C alkoxy, phenoxy, C heteroalkoxy, and at least one of E includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or wherein J is the same as J, or another member of the group defining J and E is the same as E , or another member of the group defining E ; Y are independently O, S or NR ; M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(=Y ); R and R are independently selected from the group consisting of hydrogen, C alkyls, C branched alkyls, C cycloalkyls, C substituted alkyls, C substituted cycloalkyls, aryls, substituted aryls, aralkyls, C heteroalkyls, substituted C heteroalkyls, C alkoxy, phenoxy and C heteroalkoxy; (m1) and (m2) are independently zero or one; (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer, Z is an electron withdrawing group; and R is a polymeric residue. which is optionally capped with a moiety of the formula:.

Terminally-Branched Polymeric Linkers And Polymeric Conjugates Containing The Same
view source
US Patent:

6638499, Oct 28, 2003
Filed:

Feb 6, 2002
Appl. No.:

10/067930
Inventors:

Anthony J. Martinez - Hamilton Square NJ
Annapurna Pendri - Middletown CT
Richard B. Greenwald - Somerset NJ
Yun H. Choe - Piscataway NJ
Assignee:

Enzon, Inc. - Bridgewater NJ
International Classification:

A61K 31785
US Classification:

424 783, 5147723, 514283, 514506, 514513, 514515
Abstract:

The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: E are independently selected from the group consisting of hydrogen, C alkyls, C branched alkyls, C cycloalkyls, C substituted alkyls, C substituted cycloalkyls, aryls, substituted aryls, aralkyls, C heteroalkyls, substituted C heteroalkyls, C alkoxy, phenoxy, C heteroalkoxy, and at least one of E includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or wherein J is the same as J, or another member of the group defining J and E is the same as E , or another member of the group defining E , Y are independently O, S or NR ; M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C( Y ); R and R are independently selected from the group consisting of hydrogen, C alkyls, C branched alkyls, C cycloalkyls, C substituted alkyls, C substituted cycloalkyls, aryls, substituted aryls, aralkyls, C heteroalkyls, substituted C heteroalkyls, C alkoxy, phenoxy and C heteroakoxy; (m ) and (m ) are independently zero or one; (n ), (n ), (p ), (p ) and (q) are independently zero or a positive integer, Z is an electron withdrawing group; and R is a polymeric residue. which is optionally capped with a moiety of the formula:.

Hiv Integrase Inhibitors
view source
US Patent:

7109186, Sep 19, 2006
Filed:

Jul 9, 2003
Appl. No.:

10/616031
Inventors:

Michael A. Walker - Durham CT, US
Zhuping Ma - Chandler AZ, US
B. Narasimhulu Naidu - Durham CT, US
Margaret E. Sorenson - Meriden CT, US
Annapurna Pendri - Glastonbury CT, US
Jacques Banville - St-Hubert, CA
Serge Plamondon - Ste-Catherine, CA
Roger Remillard - Napierville, CA
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 31/675
A61K 31/496
A61K 31/4015
A61K 31/541
C07D 403/06
C07D 413/06
C07D 417/06
C07D 207/36
US Classification:

514 91, 5142278, 5142322, 5142355, 51425401, 514326, 514343, 514397, 514422, 514423, 544 585, 544 60, 544 82, 544141, 544372, 546208, 5462787, 548112, 5483147, 548427, 548517, 548537
Abstract:

The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds.

Releasable Polymeric Conjugates Based On Aliphatic Biodegradable Linkers
view source
US Patent:

7122189, Oct 17, 2006
Filed:

Aug 13, 2002
Appl. No.:

10/218167
Inventors:

Hong Zhao - Edison NJ, US
Richard B. Greenwald - Somerset NJ, US
Annapurna Pendri - South Glastonbury CT, US
Assignee:

Enzon, Inc. - Bridgewater NJ
International Classification:

A61K 39/395
A01N 33/08
A01N 31/06
A61K 39/44
US Classification:

4241791, 4241811, 4241931, 4241941, 514668, 514715, 514716
Abstract:

Activated polymeric bicine derivatives such as.

Pyrazine Modulators Of Cannabinoid Receptors
view source
US Patent:

7326706, Feb 5, 2008
Filed:

Aug 12, 2004
Appl. No.:

10/917199
Inventors:

Bruce A. Ellsworth - Princeton NJ, US
Chongqing Sun - East Windsor NJ, US
Annapurna Pendri - Glastonbury CT, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A01N 43/64
A61K 31/53
A61K 31/4965
C07D 401/00
C07D 241/02
US Classification:

514241, 514242, 51425505, 51425506, 544180, 544182, 544295, 544405, 544406
Abstract:

The present application describes compounds according to Formula I, wherein A, G, Gand Rare described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents.

Azabicyclic Heterocycles As Cannabinoid Receptor Modulators
view source
US Patent:

7378418, May 27, 2008
Filed:

Dec 17, 2004
Appl. No.:

11/016135
Inventors:

Guixue Yu - Princeton Junction NJ, US
William R. Ewing - Yardley PA, US
Amarendra B. Mikkilineni - Easton PA, US
Annapurna Pendri - Glastonbury CT, US
Philip M. Sher - Plainsboro NJ, US
Samuel Gerritz - Guilford CT, US
Bruce A. Ellsworth - Princeton NJ, US
Gang Wu - Princeton NJ, US
Yanting Huang - Pennington NJ, US
Chongqing Sun - East Windsor NJ, US
Natesan Murugesan - Princeton Junction NJ, US
Zhengxiang Gu - Princeton NJ, US
Ying Wang - Princeton NJ, US
Doree Sitkoff - Dresher PA, US
Stephen R. Johnson - Erdenheim PA, US
Ximao Wu - Princeton Junction NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07D 487/04
A61K 31/4162
A61P 3/04
A61P 43/00
US Classification:

514248, 544236
Abstract:

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I:.

Pyrazole Derivatives As Cannabinoid Receptor Modulators
view source
US Patent:

7517900, Apr 14, 2009
Filed:

Oct 6, 2004
Appl. No.:

10/959866
Inventors:

Annapurna Pendri - South Glastonbury CT, US
Samuel Gerritz - Guilford CT, US
Dharmpal S. Dodd - Princeton NJ, US
Chongqing Sun - East Windsor NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 31/415
C07D 231/00
US Classification:

514404, 5483561
Abstract:

The present application describes compounds according to Formula I, wherein A, B, E, R, R, R, R, Y and Z are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents.

Tetrahydroquinoline Cannabinoid Receptor Modulators
view source
US Patent:

7709647, May 4, 2010
Filed:

Apr 17, 2008
Appl. No.:

12/104553
Inventors:

Chongqing Sun - East Windsor NJ, US
William R. Ewing - Yardley PA, US
Yanting Huang - Pennington NJ, US
Annapurna Pendri - Glastonbury CT, US
Samuel Gerritz - Guilford CT, US
Bruce A. Ellsworth - Princeton NJ, US
Natesan Murugesan - Princeton Junction NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07D 215/38
A61K 31/4709
US Classification:

546159, 514313
Abstract:

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I:.